产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
PF-06281355 (PF-1355) is an orally available, selective and potent mechanism based inhibitor of the myeloperoxidase (MPO) that reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. PF-06281355 suppresses albuminuria and chronic renal dysfunction in model of anti-Glomerular Basement Membrane (GBM) disease.
其他说明
This compound was developed by Pfizer for Nitric Oxide & Cell Stress research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
法律信息
Sold for research purposes under agreement from Pfizer Inc.
Pfizer is a registered trademark of Pfizer, Inc.
基本信息
| 经验(实验)分子式 | C14H15N3O4S |
| 分子量 | 321.35 |
| NACRES | NA.77 |
产品性质
| 质量水平 | 100 |
| 测定 | ≥98% (HPLC) |
| 形式 | powder |
| manufacturer/tradename | Pfizer® |
| 颜色 | white to beige |
| 溶解性 | DMSO: 10 mg/mL, clear (warmed) |
| 创始人 | Pfizer |
| 储存温度 | room temp |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H302 |
| 预防措施声明 | P301 + P312 + P330 |
| 危险分类 | Acute Tox. 4 Oral |
| 储存分类代码 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
m.cnreagent.com
